Investigating the Investigators: Another Headache for Drug Sponsors
This article was originally published in RPM Report
Executive Summary
One leading indicator of a more enforcement-minded approach at the Food & Drug Administration may be a crackdown on clinical trial investigators suspected of fraud. One thing is already clear: sponsors who rely on investigators who trigger suspicions will pay a price in the form of an even tougher time getting the drug through FDA.
You may also be interested in...
No Walk in the Park: FDA Talks Tough about Executive Accountability
If history is any guide, FDA will soon start showing its teeth as a regulatory enforcement agency. That makes this a good time for executives to refresh their memory about the doctrine of strict liability for FD&C Act violations-and to ponder the implications of the Department of Justice's recent use of the so-called Park doctrine against three top execs at Purdue Pharma.
No Walk in the Park: FDA Talks Tough about Executive Accountability
If history is any guide, FDA will soon start showing its teeth as a regulatory enforcement agency. That makes this a good time for executives to refresh their memory about the doctrine of strict liability for FD&C Act violations-and to ponder the implications of the Department of Justice's recent use of the so-called Park doctrine against three top execs at Purdue Pharma.
Data Integrity Delays: Another Key Takeaway from Ketek
Senator Grassley wants FDA to withhold NDAs from advisory committees if there are pending questions about the authenticity of any of the clinical data. The agency appears to agree. That could represent another roadblock to NDA reviews.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: